GSK has been the topic of several other research reports. JPMorgan Chase & Co. restated a neutral rating and issued a GBX 1,570 ($21.29) price target on shares of GlaxoSmithKline in a research report on Monday, October 2nd. Beaufort Securities restated a buy rating and issued a GBX 1,800 ($24.41) price target on shares of GlaxoSmithKline in a research report on Monday, October 23rd. Shore Capital reiterated a hold rating on shares of GlaxoSmithKline in a research report on Wednesday, September 20th. UBS Group upgraded shares of GlaxoSmithKline to a buy rating and set a GBX 1,550 ($21.02) price objective on the stock in a research report on Monday, November 27th. Finally, Societe Generale reiterated a sell rating on shares of GlaxoSmithKline in a research report on Thursday, November 9th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and nine have issued a buy rating to the company’s stock. The company has a consensus rating of Hold and an average target price of GBX 1,565.24 ($21.23).
Shares of GlaxoSmithKline (LON GSK) opened at GBX 1,359.20 ($18.43) on Monday. GlaxoSmithKline has a 1 year low of GBX 1,270 ($17.22) and a 1 year high of GBX 1,724.50 ($23.39). The firm has a market cap of $67,390.00 and a price-to-earnings ratio of 2,831.67.
The firm also recently disclosed a dividend, which was paid on Thursday, January 11th. Investors of record on Thursday, November 9th were paid a GBX 19 ($0.26) dividend. This represents a yield of 1.41%. The ex-dividend date was Thursday, November 9th.
In related news, insider Patrick Vallance sold 20,000 shares of the company’s stock in a transaction dated Monday, December 18th. The shares were sold at an average price of GBX 1,310 ($17.77), for a total value of £262,000 ($355,302.41). Also, insider Urs Rohner acquired 473 shares of the stock in a transaction that occurred on Wednesday, October 25th. The stock was acquired at an average cost of GBX 1,518 ($20.59) per share, with a total value of £7,180.14 ($9,737.10). Over the last ninety days, insiders purchased 502 shares of company stock valued at $756,702.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.